01Corporate & Portfolio Strategy
Turn scientific potential into a defensible portfolio plan.
We help leadership teams evaluate which assets to advance, pause, partner, or discontinue by integrating scientific differentiation, clinical strategy, CMC feasibility, regulatory risk, competitive positioning, and investment requirements.
- Asset and indication prioritization
- Development pathway and scenario analysis
- Stage-gate and investment decision frameworks
- Lifecycle and line-extension planning
- Portfolio risk, dependency, and resource assessment
- Executive decision materials and implementation roadmaps
02Digital Life Sciences Strategy
Build solutions that life-science companies can adopt and scale.
We help technology companies understand how pharma and biotech customers evaluate, purchase, validate, and implement digital tools. Product strategy is connected to scientific use cases, operational workflows, regulatory expectations, and measurable value.
- Market segmentation and ideal-customer profiling
- High-value use-case and workflow identification
- Product positioning and value-proposition development
- Pharma and biotech buyer-requirement analysis
- GxP, data-integrity, validation, and implementation planning
- Pilot design, success metrics, and market-entry roadmaps
03Product & CMC Development
Translate product risk into an executable CMC roadmap.
We help Heads of CMC and technical leaders determine what must be established at each stage - and in what sequence - to advance programs with confidence.
- Phase-appropriate CMC development strategies
- Product profile, CQA, and control-strategy alignment
- Process, analytical, and formulation roadmaps
- Manufacturability, scale-up, and supply planning
- CDMO selection, oversight, and technology transfer
- Comparability, PPQ, validation, and inspection readiness
04Partnerships & Technical Diligence
Understand what the asset will take to deliver.
A scientifically compelling asset is only part of a transaction. We assess what it will take to develop, manufacture, register, and supply antibody, bispecific, peptide, and oligonucleotide programs successfully.
- CMC maturity and critical development gaps
- Manufacturability and technology-transfer risks
- Analytical, control-strategy, and validation readiness
- Regulatory and comparability obligations
- CDMO, capacity, and supply-chain dependencies
- Post-transaction costs and execution priorities
